Literature DB >> 11022005

Characterization of human immunodeficiency virus type 1 vif gene in long-term asymptomatic individuals.

G Hassaïne1, I Agostini, D Candotti, G Bessou, M Caballero, H Agut, B Autran, Y Barthalay, R Vigne.   

Abstract

We have determined the sequence of the human immunodeficiency virus type 1 (HIV-1) vif genes from a cohort of 42 long-term nonprogressors (LTNP) and compared these sequences to those of 8 late progressors. The coding potential of the vif open reading frame directly derived by nested PCR from uncultured peripheral blood mononuclear cell DNA was conserved in all 50 individuals. The nucleotide distances between vif sequences were not significantly different between LTNP and late progressors, indicating similar selections of viruses within both types of long-term HIV-1-infected subjects. However, a statistically significant correlation between an amino acid signature at position 132 of Vif and the viral load was found within LTNP. Namely, amino acid Ser was associated with low viral load and amino acid Arg with high viral load. This signature was also observed when LTNP with low viral load were compared to progressors. The Ser132 signature was introduced in place of Arg132 present in the HIV-1 YU-2 Vif prototype into chimeric viruses to assess the impact of Vif signature on the virus. While the replication properties in the SupT1 cell line were unmodified, the mutagenized virus revealed a fivefold decreased replication in activated PBMC, suggesting a possible role of this Vif signature for viral production in vivo. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11022005     DOI: 10.1006/viro.2000.0543

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  16 in total

1.  Mass spectrometry analysis of HIV-1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity.

Authors:  Jared R Auclair; Karin M Green; Shivender Shandilya; James E Evans; Mohan Somasundaran; Celia A Schiffer
Journal:  Proteins       Date:  2007-11-01

2.  Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression.

Authors:  Claudia Pastori; Barbara Weiser; Claudia Barassi; Caterina Uberti-Foppa; Silvia Ghezzi; Renato Longhi; Giliola Calori; Harold Burger; Kimdar Kemal; Guido Poli; Adriano Lazzarin; Lucia Lopalco
Journal:  Blood       Date:  2006-03-07       Impact factor: 22.113

3.  The degree of HIV-1 amino acid variability is strictly related to different disease progression rates.

Authors:  Rossana Scutari; Monica Faieta; Roberta D'Arrigo; Lavinia Fabeni; Cristina Mussini; Andrea Cossarizza; Claudio Casoli; Carlo Federico Perno; Valentina Svicher; Claudia Alteri; Stefano Aquaro
Journal:  Virus Genes       Date:  2018-05-17       Impact factor: 2.332

4.  Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function.

Authors:  John S Albin; Guylaine Haché; Judd F Hultquist; William L Brown; Reuben S Harris
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

5.  Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors.

Authors:  Joel N Blankson; Justin R Bailey; Seema Thayil; Hung-Chih Yang; Kara Lassen; Jun Lai; Shiv K Gandhi; Janet D Siliciano; Thomas M Williams; Robert F Siliciano
Journal:  J Virol       Date:  2006-12-06       Impact factor: 5.103

6.  Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by a two-amino-acid insertion in HIV-1 Vif from a nonprogressing mother and child.

Authors:  Louis Alexander; Mary Janette Aquino-DeJesus; Michael Chan; Warren A Andiman
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes.

Authors:  Toshiyuki Miura; Mark A Brockman; Chanson J Brumme; Zabrina L Brumme; Jonathan M Carlson; Florencia Pereyra; Alicja Trocha; Marylyn M Addo; Brian L Block; Alissa C Rothchild; Brett M Baker; Theresa Flynn; Arne Schneidewind; Bin Li; Yaoyu E Wang; David Heckerman; Todd M Allen; Bruce D Walker
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

8.  Unexpected diversity of cellular immune responses against Nef and Vif in HIV-1-infected patients who spontaneously control viral replication.

Authors:  Leandro F Tarosso; Mariana M Sauer; Sabri Sanabani; Maria Teresa Giret; Helena I Tomiyama; John Sidney; Shari M Piaskowski; Ricardo S Diaz; Ester C Sabino; Alessandro Sette; Jorge Kalil-Filho; David I Watkins; Esper G Kallas
Journal:  PLoS One       Date:  2010-07-02       Impact factor: 3.240

9.  Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy.

Authors:  Hiroyu Hatano; Eric L Delwart; Philip J Norris; Tzong-Hae Lee; Joan Dunn-Williams; Peter W Hunt; Rebecca Hoh; Susan L Stramer; Jeffrey M Linnen; Joseph M McCune; Jeffrey N Martin; Michael P Busch; Steven G Deeks
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

Review 10.  Running loose or getting lost: how HIV-1 counters and capitalizes on APOBEC3-induced mutagenesis through its Vif protein.

Authors:  Carsten Münk; Björn-Erik O Jensen; Jörg Zielonka; Dieter Häussinger; Christel Kamp
Journal:  Viruses       Date:  2012-11-14       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.